Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma-Reference-Cited by-同舟云学术

Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma

Published:2003-10-03 Issue:8 Volume:98 Page:1627-1634
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Gravis Gwenaelle,Bladou Franck,Salem Naji,Macquart-Moulin Genevi�ve,Serment G�rard,Camerlo Jacques,Genre Dominique,Bardou Val�rie-Jeanne,Maraninchi Dominique,Viens Patrice

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. American Cancer Society. Selected cancers: prostate. In: Cancer facts and figures 2001. Atlanta: American Cancer Society, 2001: 16-17.

2. A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

3. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

4. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

5. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells;International Journal of Oncology;2015-12-14

2. Quimioterapia basada en docetaxel en el tratamiento de pacientes con cáncer de prostata resistente a la castración;Actas Urológicas Españolas;2014-10

3. Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer;Actas Urológicas Españolas (English Edition);2014-10

4. Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience;Cancer Investigation;2014-09-26

5. A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer;Chemotherapy;2014